Report Detail
Oral Mucositis - Pipeline Review, H1 2019
- RnM3373174 |
- 20 December, 2019 |
- Global |
- 126 Pages |
- Global Markets Direct |
- Pharma & Healthcare
Oral Mucositis - Pipeline Review, H2 2019
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Pipeline Review, H2 2019, provides an overview of the Oral Mucositis (Gastrointestinal) pipeline landscape.
Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oral Mucositis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Oral Mucositis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Oral Mucositis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 10, 1 and 6 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Oral Mucositis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Oral Mucositis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Oral Mucositis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Oral Mucositis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Oral Mucositis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Oral Mucositis (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Oral Mucositis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Oral Mucositis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Oral Mucositis - Overview
Oral Mucositis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Oral Mucositis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Oral Mucositis - Companies Involved in Therapeutics Development
Alivio Therapeutics Inc
Allander Biotechnologies LLC
BIOCND Inc
Clevexel Pharma SAS
Enzychem Lifesciences Corp
Galera Therapeutics Inc
Genekey Biotech Chengdu Co Ltd
GlycoMira Therapeutics Inc
Humanetics Corp
Innovation Pharmaceuticals Inc
Lakewood-Amedex Inc
Matrix Biomed Inc
Monopar Therapeutics Inc
Oragenics Inc
Soligenix Inc
Spectrum Pharmaceuticals Inc
Spherium Biomed SL
Sunny Pharmtech Inc
Oral Mucositis - Drug Profiles
AG-013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avasopasem manganese - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCD-600 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brilacidin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clonidine ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVXL-0095 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dusquetide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
genistein - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levoleucovorin calcium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mosedipimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nu-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
phenylbutyrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pralatrexate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize FGFRs for Oral Mucositis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize KGFR for Chemotherapy Induced Gastrointestinal Mucositis and Oral Mucositis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tempol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oral Mucositis - Dormant Projects
Oral Mucositis - Discontinued Products
Oral Mucositis - Product Development Milestones
Featured News & Press Releases
Nov 25, 2019: Innovation Pharmaceuticals and FDA agree to waive initial pediatric study plan requirement regarding brilacidin for the prevention of oral mucositis
Nov 13, 2019: Innovation Pharmaceuticals: Oral Cancer on the Rise; company offers perspectives on opportunity of Brilacidin for the prevention of Oral Mucositis
Oct 08, 2019: Innovation Pharmaceuticals cites recent academic literature showing host defense proteins at Cutting-Edge of Medicine for Multiple Diseases
Oct 08, 2019: Galera Therapeutics announces two-year tumor outcomes data for GC4419
Oct 03, 2019: Soligenixs SGX942 on track to fill unmet medical need; targeting oral mucositis in patients with head and neck cancer
Sep 30, 2019: Oragenics presents interim data on the AG013 phase 2 clinical trial at the European Society for Medical Oncology Congress 2019
Sep 25, 2019: Oragenics announces phase 2 clinical trial of AG013 reaches enrollment of 158 patients
Sep 23, 2019: Oragenics to present interim data on AG013 at the European Society of Medical Oncology Congress
Aug 28, 2019: Soligenix announces positive recommendation by Independent Data Monitoring Committee on its phase 3 clinical trial of SGX942 for the treatment of oral mucositis in Head and Neck Cancer
Aug 15, 2019: Soligenix Announces $150,000 NIH Small Business Innovation Research Award Supporting Evaluation of SGX942 in Pediatric Indications
May 29, 2019: Innovation Pharmaceuticals provides update on brilacidin at 2019 BIO International Convention
May 20, 2019: Oragenics provides development update of AG013 for oral mucositis
May 01, 2019: Innovation Pharmaceuticals receives FDA End-of-Phase 2 meeting minutes
Apr 23, 2019: Innovation Pharmaceuticals - JAMA Article reinforces need for novel oral mucositis treatments in supportive cancer care
Apr 09, 2019: Innovation Pharmaceuticals reports enhancements in manufacture of Brilacidin phase 3 drug supply
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Summary:
Get latest Market Research Reports on Oral Mucositis. Industry analysis & Market Report on Oral Mucositis is a syndicated market report, published as Oral Mucositis - Pipeline Review, H1 2019. It is complete Research Study and Industry Analysis of Oral Mucositis market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
